



# The 4th World Congress on **CONTROVERSIES TO CONSENSUS IN DIABETES, OBESITY AND HYPERTENSION**



**BARCELONA, SPAIN • NOVEMBER 8-11, 2012**

CO-CHAIRPERSONS

*S. Del Prato, Italy | I. Raz, Israel*

PROGRAM DIRECTORS

*S. Del Prato, Italy | P. Home, UK | I. Raz, Israel*



[www.codhy.com](http://www.codhy.com) • [codhy@codhy.com](mailto:codhy@codhy.com)



## ORGANIZING COMMITTEE

- |                           |                                  |                             |
|---------------------------|----------------------------------|-----------------------------|
| <b>W. Cefalu, USA</b>     | <b>E. Grossman, Israel</b>       | <b>P.M. Nilsson, Sweden</b> |
| <b>J. Chan, Hong Kong</b> | <b>V. Hainer, Czech Republic</b> | <b>S. Sadikot, India</b>    |
| <b>J. Davidson, USA</b>   | <b>P. Home, UK</b>               | <b>E. Standl, Germany</b>   |
| <b>R.A. DeFronzo, USA</b> | <b>M. Laakso, Finland</b>        | <b>L. Van Gaal, Belgium</b> |
|                           | <b>L.A. Leiter, Canada</b>       |                             |

## SCIENTIFIC COMMITTEE

- |                                       |                                 |                                 |
|---------------------------------------|---------------------------------|---------------------------------|
| <b>A. Avogaro, Italy</b>              | <b>L. Heinemann, Germany</b>    | <b>P. Pozzilli, Italy</b>       |
| <b>R.G. Bretzel, Germany</b>          | <b>S. Heller, UK</b>            | <b>E. Ravussin, USA</b>         |
| <b>A. Ceriello, Spain</b>             | <b>B. Hirshberg, USA</b>        | <b>F. Rubino, USA</b>           |
| <b>S. Cernea, Romania</b>             | <b>P. Iozzo, Italy</b>          | <b>L.M. Ruilope, Spain</b>      |
| <b>J.H. de Vries, The Netherlands</b> | <b>L. Ji, China</b>             | <b>G. Schernthaner, Austria</b> |
| <b>D. de Zeeuw, The Netherlands</b>   | <b>N.M. Lalic, Serbia</b>       | <b>I. Shai, Israel</b>          |
| <b>M. Donath, Switzerland</b>         | <b>H. Lebovitz, USA</b>         | <b>J. Škrha, Czech Republic</b> |
| <b>M. Federici, Italy</b>             | <b>R. Lichiardopol, Romania</b> | <b>A. Solini, Italy</b>         |
| <b>B. Frier, Scotland</b>             | <b>G. Mancia, Italy</b>         | <b>I. Tkac, Slovakia</b>        |
| <b>B. Gallwitz, Germany</b>           | <b>M.A. Nauck, Germany</b>      | <b>H. Toplak, Austria</b>       |
| <b>A.J. Garber, USA</b>               | <b>A. Nicolucci, Italy</b>      | <b>D. Tschöpe, Germany</b>      |
| <b>Y. Handelsman, USA</b>             | <b>P. Nilsson, Sweden</b>       | <b>C. Tsigos, Greece</b>        |
| <b>M. Hanefeld, Germany</b>           | <b>G. Ning, China</b>           | <b>J. Tuomilehto, Finland</b>   |
| <b>T.A.M. Heagerty, UK</b>            | <b>G. Perseghin, Italy</b>      | <b>J. Wainstein, Israel</b>     |

## PRELIMINARY FACULTY LIST

- |                                     |                                  |                             |                                   |
|-------------------------------------|----------------------------------|-----------------------------|-----------------------------------|
| <b>A. Ametov, Russia</b>            | <b>B. Gallwitz, Germany</b>      | <b>A. Lejniaks, Latvia</b>  | <b>A. Scheen, Belgium</b>         |
| <b>C. Bailey, UK</b>                | <b>A. Garber, USA</b>            | <b>D. Leroith, USA</b>      | <b>G. Schernthaner, Austria</b>   |
| <b>R. Bitzur, Israel</b>            | <b>F. Giorgino, Italy</b>        | <b>G. Lieberman, Israel</b> | <b>P. Schwarz, Denmark</b>        |
| <b>R. Bonadonna, Italy</b>          | <b>G. Grassi, Italy</b>          | <b>V. Lyssenko, Sweden</b>  | <b>J. Seufert, Germany</b>        |
| <b>F. Bonnici, South Africa</b>     | <b>E. Grossman, Israel</b>       | <b>G. Mancia, Italy</b>     | <b>M. Shestakova, Russia</b>      |
| <b>E. Bonora, Italy</b>             | <b>V. Hainer, Czech Republic</b> | <b>E. Mannucci, Italy</b>   | <b>L. Sjostrom, Sweden</b>        |
| <b>R.G. Bretzel, Germany</b>        | <b>H. Haller, Denmark</b>        | <b>G. Marchesini, Italy</b> | <b>J. Skrha, Czech Republic</b>   |
| <b>C. Barrant, USA</b>              | <b>M. Hanefeld, Germany</b>      | <b>N. Marx, Germany</b>     | <b>A. Solini, Italy</b>           |
| <b>W. Cefalu, USA</b>               | <b>S. Heller, UK</b>             | <b>J. Meier, Germany</b>    | <b>E. Standl, Germany</b>         |
| <b>A. Ceriello, Spain</b>           | <b>B. Hirshberg, Israel</b>      | <b>D. Micic, Serbia</b>     | <b>N. Stern, Israel</b>           |
| <b>O. Cohen, Israel</b>             | <b>J.C. Holm, Denmark</b>        | <b>O. Mosenzon, Israel</b>  | <b>C.J. Tack, The Netherlands</b> |
| <b>T. Cukierman-Yaffee, Israel</b>  | <b>P. Home, UK</b>               | <b>M. Mosseri, Israel</b>   | <b>R. Taylor, UK</b>              |
| <b>J. Davidson, USA</b>             | <b>B. Itzhak, Israel</b>         | <b>M. Nauck, Germany</b>    | <b>M. Theodorakis, Greece</b>     |
| <b>P.P. De Feo, Italy</b>           | <b>H. Yki-Jarvinen, Finland</b>  | <b>D. Neely, UK</b>         | <b>I. Tkac, Slovakia</b>          |
| <b>R.A. DeFronzo, USA</b>           | <b>G. Jermendy, Hungary</b>      | <b>P. Nilsson, Sweden</b>   | <b>C. Tsigos, Greece</b>          |
| <b>S. Del Prato, Italy</b>          | <b>A. Karasik, Israel</b>        | <b>P. Pozzilli, Italy</b>   | <b>L. Van Gaal, Belgium</b>       |
| <b>D. de Zeeuw, The Netherlands</b> | <b>N. Katsilambros, Greece</b>   | <b>G. Parati, Italy</b>     | <b>S. Vinker, Israel</b>          |
| <b>D. Dicker, Israel</b>            | <b>E.S. Kilpatrick, UK</b>       | <b>M. Ravid, Israel</b>     | <b>J. Vora, UK</b>                |
| <b>P. Djordjevic, Serbia</b>        | <b>Y. Kleinman, Israel</b>       | <b>I. Raz, Israel</b>       | <b>R. Weiss, Israel</b>           |
| <b>M. Puig Domingo, Spain</b>       | <b>F.K. Knop, Denmark</b>        | <b>Y. Reznik, France</b>    | <b>J. Wilding, UK</b>             |
| <b>M. Donath, Switzerland</b>       | <b>M. Laakso, Finland</b>        | <b>L.M. Ruilope, Spain</b>  | <b>R. Zimlichman, Israel</b>      |
| <b>N. Finer, UK</b>                 | <b>N. Lalic, Serbia</b>          | <b>S. Sadikot, India</b>    |                                   |

# PRELIMINARY SCIENTIFIC PROGRAM

**THURSDAY, NOVEMBER 8, 2012**

**13:00-18:00** Novo Nordisk Satellite Symposium

**19:00-20:00** **OPENING SESSION**  
**BREAKTHROUGHS IN DIABETES IN 2012**

**20:00-21:00** Welcome Reception

**FRIDAY, NOVEMBER 9, 2012**

## HALL A

**08:30-10:00** **PLENARY SESSION 1**  
**DIABETES AND CANCER**

Chairs: **S. Del Prato, Italy; I. Raz, Israel**

Pathogenesis of cancers in diabetes and obesity

**D. Leroith, USA**

Insulin therapy and cancer

**P. Home, UK**

Oral agents and cancer (Metformin, Sulfonylureas, Thiazolidinediones)

**R.A. DeFronzo, USA**

Newer therapies and cancer (incretin and SGLT2)

**M. Nauck, Germany**

DISCUSSION: Do we need malignancy outcome studies?

**10:00-10:30** Coffee Break

**10:30-12:00** **SESSION 2**  
**CONTROVERSIES IN**  
**DIABETES TREATMENT**

Chair: **P. Djordjevic, Serbia**

How to start pharmacologic treatment?  
Patho-physiological driven approach vs. Guideline approach

*Patho-physiological driven approach:*

**R.A. DeFronzo, USA**

*Guideline approach:* **I. Raz, Israel**

How do we continue treatment in secondary failure?

Incretin vs. Insulin treatment

*Incretin:* **B. Gallwitz, USA**

*Insulin:* **R.G. Bretzel, Germany**

**12:00-13:30** Lunch Break

**13:30-15:30** **SESSION 3**  
**DIABETES, OBESITY AND**  
**HYPERTENSION**

Chair: **A. Lejnieks, Latvia**

Should we be targeting subclinical organ damage?

*Yes:* **E. Grossman, Israel**

*No:* **G. Mancia, Italy**

Should our targets for control be different in the elderly?

Obesity

**C. Tsigos, Greece**

Blood pressure control

**G. Grassi, Italy**

Lipid control

**R. Bitzur, Israel**

Blood glucose control

**Y. Kleinman, Israel**

**15:30-16:00** Coffee Break

**16:00-17:30** **SESSION 4**  
**DIABETES AND RELATED**  
**DISORDERS**

Sleep disorders

**S. Sadikot, India**

Pancreatitis

**G. Marchesini, Italy**

Alzheimer's disease

**T. Cukierman-Yaffee, Israel**

# PRELIMINARY SCIENTIFIC PROGRAM

FRIDAY, NOVEMBER 9, 2012

## HALL B

**10:30-12:00** **SESSION 5**  
**NEWS IN HYPERTENSION**

Individualization of the management of hypertension

**G. Mancia, Italy**

Blood pressure (BP) variability or average BP is the main determinant of future cardiovascular (CV) outcomes

*Pro-variability of BP:* **G. Parati, Italy**

*Pro-average BP:* **L. Ruilope, Spain**

Diagnosis of hypertension should be by ambulatory monitoring

*Pro:* **E. Grossman, Israel**

*Con:* **P. Nilsson, Sweden**

**12:00-13:30** *Lunch Break*

**13:30-15:30** **SESSION 6**  
**OBESITY AND WEIGHT LOSS**

Chair: **D. Micic, Serbia**

Is obesity a brain disease?

*Yes:* **N. Stern, Israel**

*No:* **N. Finer, UK**

CV risk factors: The obesity paradox - Does it exist?

*Against:* **E. Standl, Germany**

*In favor:* **V. Hainer, Czech Republic**

Physical exercise is a core element for every patient

*Yes:* **P.P. De Feo, Italy**

*No:* **P. Schwarz, Denmark**

**15:30-16:00** *Coffee Break*

**16:00-17:30** **SESSION 7**  
**BIARIATRIC SURGERY**

Chair: **L. Sjostrom, Sweden**

Mechanism of metabolic advantage after bariatric surgery

*It's all food restrictions:* **R. Taylor, UK**

*It's all gastro-intestinal factors:*

**F.K. Knop, Denmark**

Surgery during adolescence can be justified?

*Yes:* **R. Weiss, Israel**

*No:* **J.C. Holm, Denmark**

## HALL C

**10:30-12:00** **SESSION 8**  
**UNMET NEEDS IN OBESITY**

Obesity treatments: The state of the art

**L. Van Gaal, Belgium**

Bariatric surgery in the prevention of T2DM:

Long term experiences from the SOS study

**L. Sjostrom, Sweden**

From bariatric surgery to bariatric pill

**G. Lieberman, Israel**

Combining surgery and pharmacologic treatment

**D. Dicker, Israel**

**12:30-13:30** *Lunch Break*

**13:30-15:30** **SESSION 9**  
**THE KIDNEY AS A NEW  
THERAPEUTIC PARTNER**

Chair: **G. Schernthaner, Austria**

Hyperglycaemia, hypertension, obesity, and the kidney in people with T2DM

**L. Van Gaal, Belgium**

The kidney as a new therapeutic partner

**J. Wilding, UK**

Clinical potential of SGLT-2 inhibition

**J. Seufert, Denmark**

How this new approach may help tackle clinical inertia

**M. Puig Domingo, Spain**

**15:30-16:00** *Coffee Break*

**16:00-17:30** **SESSION 10**  
**ONGOING DISCUSSIONS IN  
DIABETES AND METABOLIC  
SYNDROME**

Chair: **J. Skrha, Czech Republic**

Postprandial hyperglycaemic variability: Should we care?

*Yes:* **A. Ceriello, Spain**

*No:* **E.S. Kilpatrick, UK**

NAFLD/NASH - Is it an independent predictor of CV disease?

**E. Bonora, Italy**

**18:00-20:30** BMS/AZ Satellite Symposium

## PRELIMINARY SCIENTIFIC PROGRAM

SATURDAY, NOVEMBER 10, 2012

### HALL A

**08:30-10:00** **SESSION 11**  
**TYPE 2 DIABETES MELLITUS**

Chair: **A. Ametov, Russia**

Should we begin by replacing insulin deficiency or reducing insulin insensitivity?

*Early insulin replacement therapy:*

**A. Karasik, Israel**

*Early use of insulin sensitizers: TBA*

Early insulinization to prevent diabetes progression

**I. Raz, Israel**

**10:00-10:30** *Coffee Break*

**10:30-12:00** **SESSION 12**  
**NEWS ON THE INCRETINS**

Chair: **B. Itzhak, Israel**

New insights on the mechanisms of action of DPP-4 inhibitors

**M. Nauck, Germany**

A review of the cardiac and endothelial effects of incretin therapies

**F. Giorgino, Italy**

The pancreatic islet incretin system

**M. Donath, Switzerland**

**12:00-13:30** *Lunch Break*

**13:30-15:30** **SESSION 13**  
**INSULIN PUMP FOR T2DM**

Chair: **F. Bonnici, South Africa**

Insulin pump for T2DM:

The use of CSII in T2DM

**Y. Reznik, France**

The misuse of CSII in T2DM

**O. Cohen, Israel**

Insulin analogues

**A. Garber, USA**

Intensification of insulin therapy in primary care, which is preferable - Basal Bolus vs. Premix

Premix

*Basal Bolus: H. Yki-Jarvinen, Finland*

*Premix: O. Mosenzon, Israel*

Discussion on current indications and future trends

**15:30-16:00** *Coffee Break*

### HALL A [ continued ]

**16:00-17:30** **SESSION 14**  
**CLINICAL DEVELOPMENT  
OF GLUCOSE-LOWERING  
MEDICATIONS: GLOBAL AND  
REGIONAL**

Chair: **B. Hirshberg, Israel**

What type of data will we get from these large outcome studies?

**C. Bailey, UK**

Potential implications for clinical practice

**S. Del Prato, Italy**

A cardiologist in the endocrine world

**TBA**

Industry perspective

**B. Hirshberg, Israel**

### HALL B

**08:30-10:00** **SESSION 15**  
**NEW TREATMENT  
STRATEGIES**

Chair: **M. Shestakova, Russia**

How low blood glucose control?

*Very low: P. Pozzilli, Italy*

*Not too low: E. Bonora, Italy*

Individualization therapy- fashion or fact?

*Fashion: C.J. Tack, The Netherlands*

*Fact: J. Davidson, USA*

**10:00-10:30** *Coffee Break*

**10:30-12:00** **SESSION 16**  
**THE UNSOLVED PROBLEM OF  
HYPOGLYCAEMIA**

Chair: **G. Jermendy, Hungary**

Hypoglycaemia is of similar importance for every patient

*Yes: S. Heller, UK*

*No: M. Theodorakis, Greece*

Hypoglycaemia is of cardiovascular importance

*Yes: N. Lalic, Serbia*

*No: I. Tkáč, Slovakia*

**12:00-13:30** *Lunch Break*

# PRELIMINARY SCIENTIFIC PROGRAM

SATURDAY, NOVEMBER 10, 2012

## HALL B [ continued ]

**13:30-15:30** **SESSION 17**  
**HYPERTENSION**

Should we treat proteinuria with more than one RAAS inhibitor?

*Pro: R. Zimlichman, Israel*

*Con: D. de Zeeuw, The Netherlands*

Should albuminuria be a target of treatment in hypertension?

**H. Haller, Denmark**

Reno-protection vs. cardio-protection: A clinical dilemma

**M. Ravid, Israel**

New opportunities for kidney protection in diabetes

**A. Solini, Italy**

**15:30-16:00** *Coffee Break*

**16:00-17:30** **SESSION 18**  
**LIFESTYLE THERAPIES FOR  
DIABETES**

Prevention of diabetes: From research to practice

**W. Cefalu, USA**

Combination of GLP1 and insulin as 1st line therapy

**J. Vora, UK**

## HALL C

**08:30-10:00** **SESSION 19**  
**TYPE 2 DIABETES MELLITUS  
PART 2**

Impaired insulin secretion in T2DM

*It's all beta cell mass: J. Meier, Germany*

*It's all beta cell function: R. Bonadonna, Italy*

Genetic screening for the risk of diabetes- Valuable or worthless?

*Valuable: M. Laakso, Finland*

*Worthless: V. Lyssenko, Sweden*

**10:00-10:30** *Coffee Break*

## HALL C [ continued ]

**10:30-12:00** **SESSION 20**  
**LEARNING FROM THE  
LITERATURE**

Chair: **N. Katsilambros, Greece**

Meta-analysis in diabetes: Both a salvation and a danger

**P. Home, UK**

Is glucose control important for prevention of cardiovascular disease in diabetes?

*Yes: P. Pozzilli, Italy*

*No: E. Mannucci, Italy*

**12:00-13:30** *Lunch Break*

**13:30-15:30** **SESSION 21**  
**THE PLACE OF PPAR GAMA  
THERAPY IN T2DM**

Chair: **R.A. DeFronzo, USA**

Molecular mechanism of action of TZDs: What does the future hold?

**G. Scherthaner, Austria**

In vivo actions of PPARs: Glycemic control, insulin sensitivity, insulin secretion

**R.A. DeFronzo, USA**

TZDs: Cardiovascular benefits far outweigh the risks

**G. Scherthaner, Austria**

**15:30-16:00** *Coffee Break*

**16:00-17:30** **SESSION 22**  
**FUTURE THERAPY FOR  
DIABETES**

GPR40 and TAK875

*Clinical: C. Barrant, USA*

*Basic science: TBA*

11-beta hydroxysteroid dehydrogenase: a therapeutic target for diabetes management?

**A. Scheen, Belgium**



## PRELIMINARY SCIENTIFIC PROGRAM

SUNDAY, NOVEMBER 11, 2012

### HALL A

**08:30-10:00** **SESSION 23**  
**DEBATES IN LIPID  
MANAGEMENT**

Intolerance to statin drugs  
*Mechanisms of intolerance:* **R. Bitzur, Israel**  
*How to manage the problem:* **D. Neely, UK**

Residual CV risk in diabetes  
*We have reached the limit:* **M. Mosseri, Israel**  
*There is still potential:* **N. Marx, Germany**

**10:00-10:30** *Coffee Break*

**10:30-12:00** **SESSION 24**  
**FUTURE THERAPEUTIC  
APPROACHES**

ORIGIN trial-  
*The results/ A critical comment:*  
**S. Del Prato, Italy**

Translating the ORIGIN results into clinical  
practice  
**M. Hanefeld, Germany**

Future GLP-1R- Do they differ?  
**A. Garber, USA**



## GENERAL INFORMATION

### VENUE

Palau De Congressos De Catalunya  
Av. Diagonal, 661-671  
Barcelona 08028, Spain  
Tel: +34 (93) 364 4400  
Fax: +34 (93) 364 4401  
Website: [www.pcongresos.com](http://www.pcongresos.com)

### LANGUAGE

The official language of the Congress is English.

### REGISTRATION

	Early Registration until August 15, 2012	Late Registration from August 16, 2012	From November 1, 2012 & On Site
Participants - Physicians and Scientists	€540	€590	€650
Residents*	€380	€430	€470
Nurses and Students	€190	€240	€250

\* Refers to non-tenured junior scientists. Registration form must be accompanied by documentation of residency or a letter from the head of department confirming their status. The letter should be on the department letterhead and addressed to the Registration Department of the Congress.

ABSTRACT SUBMISSION DEADLINE:

**AUGUST 15, 2012**

## SPONSORS



Working Together in Diabetes



[www.codhy.com](http://www.codhy.com)  
[codhy@codhy.com](mailto:codhy@codhy.com)

**Headquarters and Administration:**  
53 Rothschild Boulevard  
PO Box 68  
Tel Aviv 61000, Israel  
Tel: +972-3-5666166  
Fax: +972-3-5666177  
Email: [info@comtecmed.com](mailto:info@comtecmed.com)

**Comtec Spain:**  
Bailén, 95-97  
pral. 1. a - 08009  
Barcelona, Spain  
Tel: +34-93-2081145  
Fax: +34-93-4579291  
Email: [spain@comtecmed.com](mailto:spain@comtecmed.com)

**Comtec China:**  
175 Xiang Yang Road South  
Shanghai 200031  
China  
Tel: +86-21-54660460  
Fax: +86-21-54660450  
Email: [china@comtecmed.com](mailto:china@comtecmed.com)